統合失調症治療薬「ゼプリオン水懸筋注」に関する安全性速報（ブルーレター）の発出について｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000043861.htmlThe evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
統合失調症治療薬「ゼプリオン水懸筋注」に関する安全性速報（ブルーレター）の発出について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
This page announces the Ministry of Health, Labour and Welfare's issuance of a safety alert regarding the antipsychotic drug "Zyprexa intramuscular injection." As of April 16, 2014, 21 deaths have been reported among patients using this medication since its launch in November 2013, though causality remains unclear. The ministry directed the manufacturer to revise the package insert and issue a blue letter alerting healthcare providers. Key warnings include: avoiding use in unstable patients, exercising caution regarding dosage when switching from other antipsychotics, and confirming symptom stability with oral medication before initiating treatment.
